Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: Aptamer launches new biomarker service

27th Aug 2025 10:24

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday.

----------

AIM - WINNERS

----------

Fiinu PLC, up 18% at 16.75p, 12-month range 0.425p-16.75p. The Weybridge, England-based financial technology company resumes trading on AIM, having completed its reverse takeover of Everfex PSA. Remains focused on its "flagship" Plugin Overdraft product and seeks to provide a turnkey banking as a service platform and customer support offering. Adds that it has developed advanced artificial intelligence and machine learning techniques to enhance Plugin Overdraft-related underwriting processes. Says underwriting can be offered as part of the platform or on a stand-alone basis. "The completion of the Everfex acquisition is a significant step in Fiinu's strategic journey, broadening our presence in the foreign exchange market and strengthening our capabilities in serving SME customers across Europe," says CEO Marko Sjoblom. Also, Fiinu announces the immediate appointments of Sami Kalliola as chief strategy officer, and Mark Wallace as chair of Everfex and an independent non-executive director.

----------

Aptamer Group PLC, up 14% at 0.95 pence, 12-month range 0.205p-0.95p. The York, England-based synthetic binders developer launches its biomarker discovery service, to create "a new fee-for-service revenue stream targeting the USD62.4 billion global biomarker discovery market". "The identification of new biomarkers is a key driver of innovation in healthcare, particularly in areas of high unmet medical need," Aptamer says. Expects the new service to be revenue-enhancing in the current financial year, providing opportunities for "immediate monetisation" with "minimal" investment needed upfront. Says it will allow pharmaceutical and biotechnology companies to accelerate their research & development pipelines without the need for "significant" expenditure. "With two additional biomarker discovery projects already progressing in the lab, we are excited to support our partners in accelerating the development of new treatments and diagnostics, while expanding the commercial impact of our Optimer platform," says Chief Executive Arron Tolley.

----------

AIM - LOSERS

----------

Victoria PLC, down 4.8% at 69.6p, 12-month range 37.5p-143p. The Worcester, England-headquartered flooring products company confirms the extension of 2026 maturities through its refinancing. This replaces its near-term senior debt maturities with EUR612 million in 9.875% senior secured notes due in July 2029, and a new GBP130 million super senior credit facility which matures in January 2030. Victoria says this "key milestone" brings "certainty for all stakeholders", as it makes additional liquidity available to invest in growth and improve margins, and allows time to execute its "self-help" operational improvement measures. Calls it a "strong, long-term solution" for its capital structure. Victoria says it remains confident that end-market volumes and pricing will recover in the medium term, and for now remains focused on rebuilding its credit rating, generating cash and delivering its "self-help initiatives". Expects these to deliver GBP70 million in annual earnings before interest, tax, depreciation and amortisation improvements.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to [email protected]

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Related Shares:

Aptamer GroupFiinuVictoria
FTSE 100 Latest
Value9,255.50
Change-10.30